Active Substance: Tetrabenazine.
Overview
Welcome to Dwaey, specifically on TETMODIS page.
This medicine contains an important and useful components, as it consists of
Tetrabenazineis available in the market in concentration
Tetrabenazine
May exacerbate symptoms of parkinsonism. Caution to be exercised when driving or performing skilled tasks. Pregnancy. Increased risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Monitor for emergence or worsening of depression, suicidality, or unusual changes in behavior. Caution in patients with a history of depression or prior suicide attempts or ideation.
Movement disorders, Moderate to severe tardive dyskinesia
Hypersensitivity. Lactation. Hepatic impairment. Patients who are actively suicidal, or who have untreated or inadequately treated depression.
>10% Sedation/somnolence (31%),Fatigue (22%),Insomnia (22%),Depression (19%),Akathisia (19%),Extrapyramidal event (15%),Anxiety (15%),Nausea (13%) 1-10% Irritability (9%),Bruising (6%),Vomiting (6%),Decreased appetite (4%),Dysuria (4%),Obsessive reaction (4%),Imbalance (9%),Parkinsonism/bradykinesia (9%),Dizziness (4%),Dysarthria (4%),Unsteady gait (4%),Headache (4%) Frequency Not Defined QTc prolongation,Neuroleptic malignant syndrome,Orthostatic Hypotension,Restlessness and agitation,Dysphagia,Depression and suicidality Potentially Fatal: Neuroleptic malignant syndrome (NMS).
3
Tetrabenazine act by depleting nerve endings of dopamine in the brain and is used to control movement disorders.
Tetrabenazine should not be given with or within 14 days of discontinuation of MAOI therapy. Blocks action of reserpine. Decreases effects of levodopa and worsen parkinsonism. Increased risk of extrapyramidal side effects when given with amantadine, metoclopramide, antipsychotics.
Information not available